Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer

Journal of Clinical Oncology

Volumn 17, Issue 2, 1999, Pages 585-592

  Hidalgo, Manuel ^a   Castellano, Daniel ^a   Paz Ares, Luis ^a   Gravalos, Cristina ^a   Diaz Puente, Maite ^a   Hitt, Ricardo ^a   Alonso, Silvia ^a   Cortes Funes, Hernan ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; GEMCITABINE;

ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DOSE CALCULATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MUCOSA INFLAMMATION; NEUTROPENIA; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA;

EID: 0033012340     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.2.585     Document Type: Article

References (26)

1. Evans DB, Abbruzzese JL, Rich TA: Cancer of the pancreas, in De Vita VT Jr, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology (ed 5). Philadelphia, PA, Lippincott, 1997, pp 1054-1077
2. Glimelius B, Hoffman K, Sjödén P-O, et al: Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 7:593-600, 1996
3. Hansen R, Quebbman E, Ritch P, et al: Continuous 5-fluorouacil infusion in carcinoma of the pancreas. Am J Med Sci 295:91-93, 1988
4. Crown J, Casper ES, Botet J, et al: Lack of efficacy of high-dose leucovorin and fluorouracil in patients with pancreatic adenocarcinoma. J Clin Oncol 9:1682-1686, 1991
5. DeCaprio JA, Mayer RJ, Gonin R, et al: Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: Results of a phase II trial. J Clin Oncol 9:2128-2133, 1991
6. Nicolson M, Webb A, Cunningham D, et al: Cisplatin and protracted venous infusion 5-fluorouracil (CF): good symptom relief with low toxicity in advanced pancreatic carcinoma. Ann Oncol 6:801-804, 1995
7. Rothman H, Cantrell JE, Lockich J, et al: Continuous infusion 5-fluorouracil plus weekly cisplatin for pancreatic carcinoma: A Mid-Atlantic Oncology Program study. Cancer 68:264-268, 1991
8. Auerbach M, Wampler GL, Lockich JJ, et al: Treatment of advanced pancreatic carcinoma with a combination of protracted infusional 5-fluorouracil and weekly carboplatin: A Mid-Atlantic Oncology Program study. Ann Oncol 8:439-444, 1997
9. Kelsen D, Hudis C, Niedzwiecki D, et al: A phase III comparison trial of streptozotocin, mitomycin and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma. Cancer 68:965-968, 1991
10. Cullinan S, Moertel CG, Wieand HS, et al: A phase III trial on the therapy of advanced pancreatic carcinoma: Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin. Cancer 65:2207-2212, 1990
11. Moertel CG, Engstrom P, Lavin PT, et al: Chemotherapy of gastric and pancreatic carcinoma: A controlled evaluation of combination of 5-fluorouracil with nitrosoureas and "lactones." Surgery 85:509-513, 1979
12. Hertel LW, Boder GB, Kroin JS, et al: Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine). Cancer Res 50:4417-4422, 1990
13. Huang P, Chubb S, Hertel LW, et al: Action of 2′,2′-difluoro-2′-deoxycytidine on DNA synthesis. Cancer Res 51:6110-6117, 1991
14. Casper ES, Green MR, Kelsen DP, et al: Phase II trial of gemcitabine (2′,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 12:29-34, 1994
15. Burris HA, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreatic cancer: A randomized trial. J Clin Oncol 15:2403-2413, 1997
16. Rothemberg ML, Moore MJ, Cripps MC, et al: A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 7:347-353, 1996
17. Bruckner HW, Zhou G, Haenel P, et al: Ex vivo ATP tumor testing of gemcitabine for combination chemotherapy and biochemical modulation. Proc Am Assoc Cancer Res 89:310, 1998 (abstr 2116)
18. Division of Cancer Treatment, National Cancer Institute: Guidelines for Reporting of Adverse Drug Reactions. Bethesda, MD: National Cancer Institute, 1988
19. World Health Organization: WHO Handbook for Reporting Results of Cancer Treatment (WHO Offset Publication No. 48). Geneva, Switzerland, World Health Organization, 1979
20. Lokich JJ, Bothe A, Fine N, et al: Phase I study of protracted venous infusion of 5-fluorouracil. Cancer 48:2565-2568, 1981
21. Kaye SB: Gemcitabine: Current status of phase I and II trials. J Clin Oncol 12:1527-1531, 1994
22. Santi DV, McHenry CS, Sommer A: Mechanism of interactions of thymidylate synthetase with 5-fluorodeoxyuridylate. Biochemistry 13:471-481, 1974
23. Berlin J, Voi M, Alberti D, et al: Phase I trial of gemcitabine, leucovorin and 5-fluorouracil in patients with advanced malignancies. Proc Am Soc Clin Oncol 16:207, 1997 (abstr 724)
24. Faggiuolo R, Raucci CA, Roncari A, et al: Phase I study of gemcitabine and continuous infusion of 5-fluorouracil in advanced pancreatic cancer. Proc Am Soc Clin Oncol 16:288, 1997 (abstr 1023)
25. Crino L, Scagliotti G, Marangolo M: Cisplatin-gemcitabine combination in advanced non-small cell lung cancer: A phase II study. J Clin Oncol 15:297-303, 1997
26. Cascinu S, Silva RR, Barni S, et al: Gemcitabine (GEM) and 5-fluorouracil (5-FU) in advanced pancreatic cancer: A GISCAP phase II study. Proc Am Soc Clin Oncol 17:264, 1998 (abstr 1013)